[1] |
HUOBER J, THÜRLIMANN B.
The role of combination chemotherapy in the treatment of patients with metastatic breast cancer[J]. Breast Care (Basel), 2009, 4(6): 367–372.
DOI:10.1159/000262808 |
|
[2] |
CARDOSO F, FALLOWFIELD L, COSTA A, et al.
Locally recurrent or metastatic breast cancer:ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2011, 22(Suppl 6): ⅵ25–ⅵ30.
|
|
[3] |
WILCKEN N, HORNBUCKLE J, GHERSI D.
Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer[J]. Cochrane Database Syst Rev, 2003(2): CD002747.
|
|
[4] |
CARDOSO F, COSTA A, SENKUS E, et al.
3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)[J]. Ann Oncol, 2017, 28(12): 3111.
DOI:10.1093/annonc/mdx036 |
|
[5] |
NABHOLTZ J M, BUZDAR A, POLLAK M, et al.
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:results of a North American multicenter randomized trial. Arimidex Study Group[J]. J Clin Oncol, 2000, 18(22): 3758–3767.
DOI:10.1200/JCO.2000.18.22.3758 |
|
[6] |
BONNETERRE J, BUZDAR A, NABHOLTZ J M, et al.
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma[J]. Cancer, 2001, 92(9): 2247–2258.
DOI:10.1002/(ISSN)1097-0142 |
|
[7] |
MOURIDSEN H T.
Letrozole in advanced breast cancer:the PO25 trial[J]. Breast Cancer Res Treat, 2007, 105(Suppl 1): 19–29.
|
|
[8] |
PARIDAENS R J, DIRIX L Y, BEEX L V, et al.
Phase Ⅲ study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women:the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group[J]. J Clin Oncol, 2008, 26(30): 4883–4890.
DOI:10.1200/JCO.2007.14.4659 |
|
[9] |
MAURI D, PAVLIDIS N, POLYZOS N P, et al.
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer:meta-analysis[J]. J Natl Cancer Inst, 2006, 98(18): 1285–1291.
DOI:10.1093/jnci/djj357 |
|
[10] |
ROBERTSON J F, LINDEMANN J P, LLOMBART-CUSSAC A, et al.
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer:follow-up analysis from the randomized 'FIRST' study[J]. Breast Cancer Res Treat, 2012, 136(2): 503–511.
DOI:10.1007/s10549-012-2192-4 |
|
[11] |
ELLIS M J, LLOMBART-CUSSAC A, FELTL D, et al.
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer:overall survival analysis from the phase Ⅱ FIRST Study[J]. J Clin Oncol, 2015, 33(32): 3781–3787.
DOI:10.1200/JCO.2015.61.5831 |
|
[12] |
JFR R, BONDARENKO IM, TRISHKINA E, et al.
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON):An international, randomised, double-blind, phase 3 trial[J]. Lancet, 2016, 388(10063): 2997–3005.
DOI:10.1016/S0140-6736(16)32389-3 |
|
[13] |
YARDLEY D A, NOGUCHI S, PRITCHARD K I, et al.
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer:BOLERO-2 final progression-free survival analysis[J]. Adv Ther, 2013, 30(10): 870–884.
DOI:10.1007/s12325-013-0060-1 |
|
[14] |
DI LEO A, JERUSALEM G, PETRUZELKA L, et al.
Results of the CONFIRM phase Ⅲ trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol, 2010, 28(30): 4594–4600.
DOI:10.1200/JCO.2010.28.8415 |
|
[15] |
DI LEB A, JERUSALEM G, PETRUZELKA L, et al.
Final overall survival:fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial[J]. J Natl Cancer Inst, 2014, 106(1): djt337.
DOI:10.1093/jnci/djt337 |
|
[16] |
FINN R S, CROWN J P, LANG I, et al.
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18):a randomised phase 2 study[J]. Lancet Oncol, 2015, 16(1): 25–35.
DOI:10.1016/S1470-2045(14)71159-3 |
|
[17] |
FINN R S, MARTIN M, RUGO H S, et al.
Palbociclib and letrozole in advanced breast cancer[J]. N Engl J Med, 2016, 375(20): 1925–1936.
DOI:10.1056/NEJMoa1607303 |
|
[18] |
HORTOBAGYI G N, STEMMER S M, BURRIS H A, et al.
Ribociclib as first-line therapy for HR-positive, advanced breast cancer[J]. N Engl J Med, 2016, 375(18): 1738–1748.
DOI:10.1056/NEJMoa1609709 |
|
[19] |
GOETZ M P, TOI M, CAMPONE M, et al.
MONARCH 3:Abemaciclib as initial therapy for advanced breast cancer[J]. J Clin Oncol, 2017, 35(32): 3638–3646.
DOI:10.1200/JCO.2017.75.6155 |
|
[20] |
CRISTOFANILLI M, TURNER N C, BONDARENKO I, et al.
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3):final analysis of the multicentre, double-blind, phase 3 randomised controlled trial[J]. Lancet Oncol, 2016, 17(4): 425–439.
DOI:10.1016/S1470-2045(15)00613-0 |
|
[21] |
SLEDGE G W, TOI M, NEVEN P, et al.
MONARCH 2:Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy[J]. J Clin Oncol, 2017, 35(25): 2875–2884.
DOI:10.1200/JCO.2017.73.7585 |
|
[22] |
SLAMON D J, NEVEN P, CHIA S, et al.
Phase Ⅲ randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer:MONALEESA-3[J]. J Clin Oncol, 2018, 36(24): 2465–2472.
DOI:10.1200/JCO.2018.78.9909 |
|
[23] |
BACHELOT T, BOURGIER C, CROPET C, et al.
Randomized phase Ⅱ trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors:a GINECO study[J]. J Clin Oncol, 2012, 30(22): 2718–2724.
DOI:10.1200/JCO.2011.39.0708 |
|
[24] |
ROYCE M, BACHELOT T, VILLANUEVA C, et al.
Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer:A Clinical Trial[J]. JAMA Oncol, 2018, 4(7): 977–984.
DOI:10.1001/jamaoncol.2018.0060 |
|
[25] |
KORNBLUM N, ZHAO F M, MANOLA J, et al.
Randomized phase Ⅱ trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy:Results of PrE0102[J]. J Clin Oncol, 2018, 36(16): 1556–1563.
DOI:10.1200/JCO.2017.76.9331 |
|
[26] |
WILSON F R, VARU A, MITRA D, et al.
Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer[J]. Breast Cancer Res Treat, 2017, 166(1): 167–177.
DOI:10.1007/s10549-017-4404-4 |
|
[27] |
KLOKE O, KLAASSEN U, OBERHOFF C, et al.
Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy:results of a randomized trial. Essen Breast Cancer Study Group[J]. Breast Cancer Res Treat, 1999, 55(1): 51–59.
DOI:10.1023/A:1006169012544 |
|
[28] |
LIM S, LEE S, HAN J, et al.
Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer[J]. Breast, 2013, 22(6): 1205–1209.
DOI:10.1016/j.breast.2013.08.013 |
|
[29] |
DUFRESNE A, PIVOT X, TOURNIGAND C, et al.
Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer[J]. Int J Med Sci, 2008, 5(2): 100–105.
|
|
[30] |
BERTELLI G, GARRONE O, BERTOLOTTI L, et al.
Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer[J]. Oncology, 2005, 68(4-6): 364–370.
DOI:10.1159/000086976 |
|
[31] |
ALBA E, RUIZ-BORREGO M, MARGELÍ M, et al.
Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer:GEICAM 2001-01 study[J]. Breast Cancer Res Treat, 2010, 122(1): 169–176.
DOI:10.1007/s10549-010-0860-9 |
|
[32] |
PARK Y H, JUNG K H, IM S A, et al.
Phase Ⅲ, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy:KCSG-BR07-02[J]. J Clin Oncol, 2013, 31(14): 1732–1739.
DOI:10.1200/JCO.2012.45.2490 |
|
[33] |
SI W, ZHU YY, LI Y, et al.
Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer[J]. Braz J Med Biol Res, 2013, 46(12): 1074–1081.
DOI:10.1590/1414-431X20133168 |
|
[34] |
DONG G L, JIA Y, WANG X R, et al.
The comparison of maintenance treatment with capecitabine (CMT) and non-maintenance treatment with capecitabine (non-CMT) in patients with metastatic breast cancer[J]. Int J Clin Exp Med, 2015, 8(5): 8283–8287.
|
|
[35] |
SURMELI Z G, VAROL U, CAKAR B, et al.
Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer[J]. Oncol Lett, 2015, 10(4): 2598–2602.
DOI:10.3892/ol.2015.3546 |
|
[36] |
赵韬, 邵清, 张汀荣, 等.
希罗达在转移性乳腺癌维持治疗中的疗效观察[J]. 实用临床医药杂志, 2011, 15(7): 88–90.
|
|
[37] |
CHEN X L, DU F, HONG R X, et al.
Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer[J]. Chin J Cancer, 2016, 35: 39.
DOI:10.1186/s40880-016-0101-7 |
|
[38] |
LIANG X, YAN Y, WANG L N, et al.
First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients[J]. Oncol Lett, 2015, 9(2): 987–993.
DOI:10.3892/ol.2014.2787 |
|
[39] |
齐帆.晚期乳腺癌维持治疗的优化及循环肿瘤DNA在临床应用的探索性研究[D].北京: 中国人民解放军军事医学科学院, 2015.
http://cdmd.cnki.com.cn/Article/CDMD-90106-1015386813.htm |
|